Colorectal cancer diagnoses soar among younger adults for one key reason
According to two studies by the American Cancer Society (ACS), there's been a recent surge in colorectal cancer in people aged 45 to 49.
ACS scientists found that after 15 years of stable colorectal cancer (CRC) trends, U.S. diagnoses of local-stage disease skyrocketed in this age group from 2019 to 2022 — including a 50% relative increase from 2021 to 2022.
Prostate Cancer Screening After 70: Experts Question Guidance After Biden's Diagnosis
"It is promising news, because the uptick in cases is likely due to first-time screening in the wake of new recommendations for younger, average-risk adults to begin testing for colorectal cancer earlier," lead author Elizabeth Schafer, an associate scientist and cancer researcher at ACS, commented in a press release.
In 2018, ACS lowered the recommended age for CRC screenings from 50 to 45. The United States Preventive Services Task Force (USPSTF) enforced the same guidance in 2021.
Read On The Fox News App
In the first study, published in the Journal of the American Medical Association (JAMA), the researchers analyzed CRC diagnoses from 2004 to 2022 among adults aged 20 to 54, sorted by age, location and stage at diagnosis.
'Western Diet' Blamed For Growing Risk Of Gi Cancers Among Young Adults
Diagnoses have increased by 1.6% each year since 2004 in the 20 to 39 age group, and by more than 2% annually since 2012 in those aged 40 to 44 and 50 to 54.
A 1.1% annual increase in people 45 to 49 years old accelerated to 12% per year from 2019 to 2022.
The ACS confirmed the increase was driven by the detection of local-stage tumors, which increased by nearly 19% each year for colon cancer and more than 25% for rectal cancer in that timeframe.
Before this period, colon cancer detection rates had been stable, and rectal cancer detection rates had been declining.
Rare Cancer Diagnoses Surge Dramatically Among Millennials And Gen X
Advanced-stage disease also continues to steeply increase, ACS reported, rising from 1.7% to 2.9% annually since 2004 among adults under 45 and "even more rapidly" in the past 10 years in those aged 45 to 54.
These findings led to another ACS study, also published in JAMA, which found that CRC screening among U.S. adults between 45 and 49 increased by 62% from 2019 to 2023.
The scientists analyzed the data of more than 50,000 individuals to compare changes in screening. They found that CRC screening, which was at 20% in 2021, jumped to 37% in 2023.
Among 45- to 49-year-olds, colonoscopy screening increased by 43%, and stool-based testing increased more than five times from 2019 to 2023.
Lead author Jessica Star, associate scientist at ACS in Atlanta, considers it "thrilling" to see this increase in screening among younger individuals, as it's likely linked to earlier-stage diagnoses.
"However, we still have a long way to go," she said in the release. "Screening for colorectal cancer in ages 45 to 49 remains suboptimal, and has not increased equitably by both educational attainment and insurance status."
Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, said the increase in screening is "successful in detecting more cancers at an early stage where the chance of cure is very high."
Click Here To Sign Up For Our Health Newsletter
"This ultimately should mean that fewer people are diagnosed later in life and fewer people have advanced colon cancer," Oberstein, who was not involved in the study, told Fox News Digital.
"This study reinforces the need to focus research on understanding the causes of colon cancer increases – and possible steps to reduce these cases."
The rate of colon cancer in those under 45 remains "substantially lower," he noted, "so it is not clear yet if universal screening at a younger age is beneficial."
Some specific patients who are younger than 45 may benefit from earlier screening, however, such as those with a family history or personal risk factors, the oncologist added.
Exercise Program Reduces Common Cancer Recurrence And Boosts Survival
As colon cancer continues to increase in younger individuals, Oberstein recommends contacting a doctor if any concerning symptoms are noticed.
Dr. Craig Eagle, chief medical officer of Guardant Health in California, added that early detection is "crucial," noting that the five-year survival rate for CRC is over 90% when the disease is caught in early stages.
For more Health articles, visit www.foxnews.com/health
"[This] plummets to 13% in late stages when symptoms usually appear," Eagle, who also was not involved in the research, told Fox News Digital.
"The rise in diagnoses for those in their 40s is an alarming reminder that screening must be easier and more accessible to reach the 50 million Americans who remain unscreened."Original article source: Colorectal cancer diagnoses soar among younger adults for one key reason
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
34 minutes ago
- Medscape
Psoriasiform Dermatitis Risk in Children on TNFi Reviewed
TOPLINE: Older age at TNF alpha inhibitors initiation, a diagnosis of juvenile idiopathic arthritis (JIA), and concomitant immunomodulator use were associated with delayed onset of paradoxical psoriasiform dermatitis (PD) in children treated with TNFi, in a retrospective chart review. METHODOLOGY: Researchers conducted a retrospective chart review of 3418 patients receiving TNFi therapy for various conditions (including Crohn's disease, JIA, and ulcerative colitis) at Cincinnati Children's Hospital Medical Center, Cincinnati, from January 2018 to January 2023. Overall, 70 patients (2%) developed PD skin eruptions (52.9% women; 91.4% White; 5.7% Black; median age at TNFi initiation, 11.7 years; median age at PD onset, 13.6 years); 21.4% of patients were given concomitant immunomodulators; 94% of patients had PD at multiple sites. The median time from starting a TNFi to the onset of PD was 16.9 months. Treatments for PD included topical steroids (85.7%), systemic medications (15.4%), and nonsteroid topicals including tacrolimus, pimecrolimus, and calcipotriene (24.3%). PD outcomes and factors associated with its severity were evaluated. TAKEAWAY: PD rashes resolved in 32 patients (45.7%); the median time to resolution was 15.5 months. Most (71.4%) of those with PD had Crohn's disease, and infliximab (52.7%) and adalimumab (44.6%) were the most frequently used TNFi. The initial TNFi was discontinued in 40 patients (57.1%) because of PD in 23 (57.5) of those patients. Of these 40 patients, 12 (30%) switched to another TNFi with a 33% recurrence rate, while 25 (62.5%) switched to a different medication class with PD persisting in 36%. Girls were more likely to receive high-potency topical steroids, possibly indicating a difference in prescribing practices or worse disease. Onset of PD occurred later in patients with JIA (coefficient estimate [CE], 22.6 months; P = .02), those on concomitant immunomodulators (CE, 11.0; P = .04), or those who were older when the TNFi was started (CE, 2.4; P < .01). IN PRACTICE: 'Our study found that the diagnosis of JIA, older age at TNFi initiation, and concomitant immunomodulation are potential predictors of later PD onset,' the authors of the study concluded. 'Female sex may influence PD severity,' they added, 'but conflicting results and the retrospective design of this study call for additional research to better understand the factors contributing to PD severity in pediatrics.' SOURCE: This study was led by Muayad M. Shahin, University of Cincinnati College of Medicine, Cincinnati, and was published online on July 31, 2025, in Pediatric Dermatology. LIMITATIONS: The retrospective study design limited the availability of detailed morphologic descriptions. Additionally, multiple definitions of severe PD restricted analysis of risk factors across different outcome measures. DISCLOSURES: This research was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases Core Center and the University of Cincinnati Office of Research medical student summer research award, funded by the Stella and Carey Wamsley Charitable Trust. One author disclosed serving as a consultant for LEO Pharma. The other authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
34 minutes ago
- Medscape
Rural Parents See More Care Gaps and Delays After Pregnancy
TOPLINE: Parents in the year following birth residing in rural areas experienced more healthcare barriers, including reduced access to obstetric care and increased emergency department visits, than their urban counterparts. While infant care was similar between rural and urban areas, postpartum parents reported delays in medical care compared with their infants in both settings. METHODOLOGY: Researchers conducted a cross-sectional analysis using data from the National Health Interview Survey to examine rural-urban differences in healthcare access in postpartum parents and infants. They included nonpregnant women aged 18-49 years who had infants aged 1 year or younger. A total of 2019 postpartum parents (mean age, 27.1 years) and 2191 infants residing in rural areas, and 12,112 postpartum parents (mean age, 29.2 years) and 13,088 infants residing in urban areas were included in the study. Self-rated health was assessed on a five-point scale ranging from excellent to poor for both postpartum parents and infants. Healthcare utilization was evaluated based on the location where the care was received, the number of office or emergency department visits in the prior year, visits to specific clinicians, and the number of hospitalizations. Barriers to care were categorized into insurance coverage issues (such as gaps in coverage, losing coverage after pregnancy, or changes in care location) and reasons for delayed medical care. TAKEAWAY: Parents residing in rural areas were less likely to see an obstetrician-gynecologist (P = .002), visited the emergency department more frequently (P = .030), and had more hospitalizations (P = .041) than those residing in urban areas. Parents residing in rural areas experienced more disruptions in medical care, gaps in insurance coverage, and loss of Medicaid coverage after pregnancy than their urban counterparts. Delays in medical care were also more prevalent among parents residing in rural vs urban areas (20.3% vs 15.8%; P = .009); this pattern was not observed among infants. Among both rural and urban parent-infant dyads, adults were more likely to experience uninsurance and delayed medical care than their infants. Cost was a more common reason for delayed care among postpartum parents than among infants in the same household, regardless of where they lived. IN PRACTICE: 'Investments in rural health care infrastructure may support rural families,' the authors wrote. 'Integrating and incentivizing care for postpartum parents alongside their infants may address differential use and access to care in this critical period.' SOURCE: The study was led by Sara C. Handley, MD, MSCE, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. It was published online on August 3, 2025, in The Journal of Rural Health. LIMITATIONS: The analysis did not include specific weighting to represent the US population of parent-infant dyads. The cross-sectional design did not specify the age of the infant, which could have affected the reported number of visits and limited comments on completeness of the care. DISCLOSURES: The study received support through grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the University of Minnesota Foundation Rural Health Research Center Fund, and the Federal Office of Rural Health Policy. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Healthcare Visits Increase Up to 15 Years Before MS Onset
TOPLINE: Healthcare use was elevated much earlier than previously recognized among patients with multiple sclerosis (MS) in new research. Physician visits for 'ill-defined symptoms and signs' increased from 15 years before MS symptom onset and mental health-related and psychiatry visits increased 14 years and 12 years before, respectively. However, nervous system-related and neurology visits increased significantly only 4 years and 8 years before the onset of MS symptoms. METHODOLOGY: The cohort study included more than 2000 patients with MS (mean age at symptom onset, 38 years; 74% women) with a known date of MS symptom onset. Data were obtained from the British Columbia MS clinical database (1991-2018). Each patient with MS was matched by sex, birth year, socioeconomic status, and postal code at the year of MS onset with up to five individuals without MS randomly selected from the general population in British Columbia. Researchers compared annual rates of physician visits during the 25 years before MS onset between the cohorts. They also compared the difference in annual physician visit rates during the 15 years before MS onset on the basis of the International Classification of Diseases, Ninth Revision chapter and physician specialty. TAKEAWAY: All-cause physician visit rate ratios (RRs) for patients with MS were consistently elevated from 14 years before MS onset (adjusted RR, 1.2; 95% CI, 1.1-1.3), peaking in the year before MS onset (adjusted RR, 1.3; 95% CI, 1.2-1.4). Mental health-related and psychiatry visits increased significantly from 14 years and 12 years before MS onset (RRs; 1.8 and 2.6, respectively), with both remaining elevated in most subsequent years. In contrast, neurology visits were significantly elevated for up to 8 years before MS onset (RR, 1.6) and nervous system conditions were elevated from only 4 years before (RR, 1.4), both peaking in the year before onset. Healthcare visits for ill-defined symptoms and signs consistently exceeded 1.15 from 15 years before MS onset, peaking in the year before (RR, 1.4). IN PRACTICE: 'MS can be difficult to recognize as many of the earliest signs — like fatigue, headache, pain, and mental health concerns — can be quite general and easily mistaken for other conditions,' study investigator Helen Tremlett, The University of British Columbia and Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada, said in a press release. 'Our findings dramatically shift the timeline for when these early warning signs are thought to begin. By identifying these earlier red flags, we may eventually be able to intervene sooner — whether that's through monitoring, support, or preventive strategies,' Tremlett added. SOURCE: This study was led by Marta Ruiz-Algueró, MD, PhD, The University of British Columbia and Djavad Mowafaghian Centre for Brain Health. It was published online on August 1 in JAMA Network Open. LIMITATIONS: This study lacked detailed clinical information and only considered issues that prompted individuals to seek medical care. Potential miscoding or misclassification may have occurred. Additionally, a potential recall bias and challenges with medical history taking may have influenced the findings. DISCLOSURES: This study was funded in part by the National Multiple Sclerosis Society and MS Canada. Several investigators reported having financial ties with various sources either during the conduct of the study or outside the submitted work. Full details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
